Daewoong pharmaceutical (069620.KS) Earnings Analysis

Daewoong pharmaceutical (069620.KS) next reports earnings on 2026-08-18. It has beaten estimates in 0/3 recent quarters (0%). Trailing P/E 7.13.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 069620.KS next report earnings?

Next earnings date2026-08-18
Consensus EPS estimaten/a
Revenue estimate398.30B

069620.KS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-097,807.9 KRWn/an/an/a
2025-11-144,030.02 KRWn/an/an/a
2025-04-281,903 KRW2,329.77 KRW-18.3%Miss
2025-02-10-1,115.1 KRW2,375.27 KRW-146.9%Miss
2024-08-0999 KRW2,224.46 KRW-95.5%Miss

Beat rate: 0/3 (0%) over reported quarters with consensus data.

069620.KS valuation and analyst view

Trailing P/E7.13
Trailing EPS17,248.81 KRW
Price / book1.40
Dividend yield0.48%
Market cap1377.30B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Daewoong pharmaceutical (069620.KS)'s next earnings date?

Daewoong pharmaceutical is next scheduled to report on 2026-08-18 and revenue estimate of 398.30B.

Did 069620.KS beat earnings last quarter?

Consensus estimate data was not available for 069620.KS's 2026-02-09 report.

What is 069620.KS's earnings track record?

Over the last 3 reported quarters with consensus data, 069620.KS beat estimates 0 times (0%).

What is 069620.KS's current P/E ratio and EPS?

069620.KS trades at a trailing P/E of 7.13 on trailing EPS of 17248.812289634934 KRW.

What do analysts rate 069620.KS?

069620.KS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.